Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on August 31, 2006

Stroke. 2006
Published online before print August 31, 2006, doi: 10.1161/01.STR.0000240690.69406.28
A more recent version of this article appeared on October 1, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
37/10/2640    most recent
01.STR.0000240690.69406.28v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Endres, M.
Right arrow Articles by Laufs, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Endres, M.
Right arrow Articles by Laufs, U.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITRIC OXIDE
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Other Stroke Treatment - Medical
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Acute Cerebral Infarction
Right arrow Emergency treatment of Stroke

Submitted on March 15, 2006
Revised on June 19, 2006
Accepted on July 31, 2006

Discontinuation of Statin Treatment in Stroke Patients

Matthias Endres MD* and Ulrich Laufs MD

From the Klinik und Poliklinik für Neurologie (M.E.), Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany; and the Klinik für Innere Medizin III (U.L.), Universität des Saarlandes, Homburg, Germany.

* To whom correspondence should be addressed. E-mail: matthias.endres{at}charite.de.

Background and Purpose--Statins reduce the risk for myocardial infarctions and stroke which may in part depend on cholesterol-independent (pleiotropic) vasoprotective effects. Here, we review evidence to suggest that the abrupt discontinuation of statin medication exerts negative vascular effects in patients with acute vascular events.

Summary of Review--It is increasingly recognized that statins (HMG-CoA reductase inhibitors) exert rapid cholesterol-independent effects. Cessation of statin treatment confers overshoot activation of heterotrimeric G-proteins Rho and Rac causing production of reactive oxygen species and suppression of NO bioavailability. In humans, discontinuation of statin therapy leads to a proinflammatory, prothrombotic state with impaired endothelium function. In patients with acute coronary syndromes, abrupt discontinuation of statin therapy significantly increases morbidity and mortality, whereas in stable vascular patients discontinuation may be safe. Recent prospective data indicated that the cessation of statin medication in acute ischemic stroke patients confers a significantly higher likelihood of early neurological deterioration and poor outcome.

Conclusions--We propose that in all acute ischemic stroke patients chronically treated with statins before the event, treatment should be continued and the patient should receive medication at the day of the stroke.


Key words: acute Rx • acute stroke • brain ischemia • cholesterol • lipids • statins • treatment




This article has been cited by other articles:


Home page
HeartHome page
U Laufs, F Custodis, and M Bohm
Who does not need a statin: too late in end-stage renal disease or heart failure?
Heart, September 1, 2008; 94(9): 1138 - 1140.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
M. Rodriguez-Yanez, J. Agulla, R. Rodriguez-Gonzalez, T. Sobrino, and J. Castillo
Review: Statins and stroke
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 157 - 166.
[Abstract] [PDF]


Home page
NeurologyHome page
L. Mascitelli, F. Pezzetta, J. Castillo, M. Blanco, A. Davalos, and S. de Compostela
STATIN TREATMENT WITHDRAWAL IN ISCHEMIC STROKE: A CONTROLLED RANDOMIZED STUDY
Neurology, May 6, 2008; 70(19): 1720 - 1721.
[Full Text] [PDF]


Home page
StrokeHome page
J. Ponce, N. P. de la Ossa, O. Hurtado, M. Millan, J. F. Arenillas, A. Davalos, and T. Gasull
Simvastatin Reduces the Association of NMDA Receptors to Lipid Rafts: A Cholesterol-Mediated Effect in Neuroprotection
Stroke, April 1, 2008; 39(4): 1269 - 1275.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
V. Prinz, U. Laufs, K. Gertz, G. Kronenberg, M. Balkaya, C. Leithner, U. Lindauer, and M. Endres
Intravenous Rosuvastatin for Acute Stroke Treatment: An Animal Study
Stroke, February 1, 2008; 39(2): 433 - 438.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
F. Colivicchi, A. Bassi, M. Santini, and C. Caltagirone
Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke
Stroke, October 1, 2007; 38(10): 2652 - 2657.
[Abstract] [Full Text] [PDF]